Dr. Brett T. Brinker, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Emory University School of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 518
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: Emory University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MI license 4301087238
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Spectrum Health Grand Rapids, MI
- Mercy Health Saint Mary's Grand Rapids, MI
- Spectrum Health United Hospital Greenville, MI
- Corewell Health Zeeland Hospital Zeeland, MI
- Corewell Health Pennock Hospital Hastings, MI
Medical groups
- Center for Physical Rehabilitation and Therapy LP (369 clinicians)
- Center for Physical Rehabilitation Inc (357 clinicians)
- Cancer and Hematology Centers of Western Mi, P.c. (110 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 518
- Services billed
- 161,378
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 8,820 | 11 |
| Injection, bortezomib, 0.1 mg | 3,150 | 16 |
| Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | 2,540 | 17 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,472 | 69 |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 1,490 | 13 |
| Insertion of needle into vein for collection of blood sample | 1,448 | 240 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,431 | 239 |
| Blood test, comprehensive group of blood chemicals | 989 | 234 |
| Injection, palonosetron hcl, 25 mcg | 960 | 39 |
| Gammaglobulin (immune system protein) measurement | 888 | 84 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Grand Rapids, MI | 905 |
| Dexamethasone Other prescribers in Grand Rapids, MI | 278 |
| Revlimid (lenalidomide) | 248 |
| Pomalyst (pomalidomide) | 132 |
| Calquence (acalabrutinib maleate) | 131 |
| Brukinsa (zanubrutinib) | 129 |
| Lenalidomide | 124 |
| Hydroxyurea Other prescribers in Grand Rapids, MI | 122 |
| Imbruvica (ibrutinib) | 120 |
| Venclexta (venetoclax) | 115 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 14 payments worth $326 in total to this clinician.
| Genzyme Corporation | $96.74 |
|---|---|
| Merck Sharp & Dohme LLC | $63.59 |
| Kyowa Kirin, Inc. | $29.93 |
| Beone Medicines USA, Inc. | $29.32 |
| E.r. Squibb & Sons, L.l.c. | $28.55 |
| Amneal Pharmaceuticals LLC | $27.23 |
| Kite Pharma, Inc. | $18.68 |
| Syndax Pharmaceuticals, Inc. | $18.02 |
| Food and Beverage | $326 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 5 companies. The companies reported $305,018 in research payments for these studies, mostly to the institutions running them.
- Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma
Genentech, Inc. - A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Beone Medicines Ltd. · Recruiting · NCT06742996 - A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Beone Medicines Ltd. · Recruiting · NCT06943872 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
AbbVie Inc. · Active, not recruiting · NCT04401748 - A Randomized, Open-label Phase 3 Study of Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
Amgen Inc. - M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
AbbVie Inc. - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
AbbVie Inc. - A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects 65 Years with Previously Untreated…
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.